OncoMatch/Clinical Trials/NCT07282834
Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)
Is NCT07282834 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for peritoneal (metastatic) cancer.
This research study aims to improve the treatment of Peritoneal Carcinomatosis (PC), a condition where cancer spreads within the abdomen. Patients with PC often experience significant pain and nutritional problems. Currently, there isn't a standard treatment approach, and doctors use different combinations of chemotherapy, surgery, and methods to deliver chemotherapy directly into the abdomen (intra-peritoneal or "IP" chemotherapy). The study will compare two IP chemotherapy methods: HIPEC and PIPAC. HIPEC involves circulating heated chemotherapy through the abdomen during surgery, while PIPAC delivers chemotherapy as a pressurized aerosol during a laparoscopic procedure. Both methods aim to achieve the same goal, but they haven't been directly compared to see which is safer, more tolerable, more effective, and provides better value.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Disease stage
Metastatic disease required
Prior therapy
Must have received: systemic chemotherapy
Receipt of at least three months of standard systemic chemotherapy prior with persistence of disease at the time of randomization
Cannot have received: investigational drug
Any investigational drug use within 30 days prior to enrollment
Cannot have received: systemic therapy
Systemic therapy within 14 days prior to randomization
Lab requirements
Blood counts
Hemoglobin < 7 gm/dL, WBC < 3,000/mm3, Platelet count < 50,000/mm3 (exclusion)
Kidney function
clinically significant renal disease (exclusion)
Liver function
AST/SGOT > 2.5x ULN, ALT/SGPT > 2.5x ULN, Total bilirubin > 2.5x ULN (exclusion)
Laboratory abnormalities that indicate clinically significant hematologic, hepatobiliary, or renal disease: AST/SGOT > 2.5x ULN, ALT/SGPT > 2.5x ULN, Total bilirubin > 2.5x ULN, Hemoglobin < 7 gm/dL, White blood cell count < 3,000/ mm3, Platelet count < 50,000/mm3
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Allegheny Health Network West Penn Hospital · Pittsburgh, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify